- What we do
-
-
Routes of delivery
- Oral
- Nasal
- Pulmonary
- Parenteral
-
Development stage
- Pre-clinical
- Phase I to Phase II
- Phase III - Commercial
Our Approach
- Choosing Your CDMO Partner
- Project Management
-
- About us
-
-
A CDMO like no other
- About Us
- Our Facilities
- Our History
- Awards and Achievements
-
Leadership Expertise
- Executive Leadership Team
- Board of Directors
- Careers
-
-
- Resources
- Events
- Contact

This whitepaper explores how spray drying can be used to create dry powders containing small molecules and much larger, more complex molecular structures such as biologics. These dry powder biologics require more complex assay techniques than those typically used for dosage forms containing small molecule APIs
Whitepaper Contents.
An overview of how spray drying has evolved from oral small molecule delivery to broader applications
Insights into the use of spray drying for formulating complex biologics, including peptides, antibodies, and vaccines
Discussion of the unique challenges involved in spray drying biologics
Identification of critical analytical techniques for assessing biologic structure and stability
Guidance on selecting assays to evaluate physical, chemical, and functional attributes
Strategies for maintaining functional activity of biologics after spray drying and during storage
Practical considerations for developing robust, stable spray-dried biologic formulations
Meet our experts

Dr. Richard Johnson
Chief Scientific Officer & Founder,
Upperton Pharma Solutions